Pacira Biosciences
PCRX
Operating Margin for Pacira Biosciences (PCRX)
Operating Margin as of April 2024 (TTM): -3.05%
According to Pacira Biosciences 's latest financial reports and stock price the company's current Operating Margin is -3.05%. At the end of 2022 the company had an Operating Margin of 7.99%.
Operating Margin history for Pacira Biosciences from 2010 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | 7.99% | -50.92% |
| 2021 | 16.28% | 49.71% |
| 2020 | 10.87% | 255.44% |
| 2019 | 3.06% | -52.06% |
| 2018 | 6.38% | -174.89% |
| 2017 | -8.52% | -23.5% |
| 2016 | -11.14% | -381.71% |
| 2015 | 3.95% | -248.44% |
| 2014 | -2.66% | -96.01% |
| 2013 | -66.74% | -48.32% |
| 2012 | -129.14% | -43.85% |
| 2011 | -229.98% | 49.7% |
| 2010 | -153.63% | -19.24% |
| 2009 | -190.24% | -41.6% |
| 2008 | -325.77% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Zogenix ZGNX | -259.55% | 8,409.90% | 🇺🇸 USA |
 Recro Pharma
REPH | 4.99% | -263.76% | 🇺🇸 USA |
 Omeros Corporation OMER | 0.00% | N/A | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | -79.07% | 2,492.51% | 🇺🇸 USA |
 Heron Therapeutics HRTX | -169.05% | 5,442.62% | 🇺🇸 USA |
 Cara Therapeutics
CARA | -209.07% | 6,754.75% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.